ADVFN Logo ADVFN
시장 데이터
뉴스
도구
시장
팔로우

Hot Features

피드 팔로우

Follow Feed 커뮤니티에서 거래자 및 투자자와 연결하세요.

실시간 옵션 플로우

포괄적인 옵션 데이터를 탐색하고 옵션 흐름으로 고급 필터를 사용하세요.

모니터

터미널 모니터로 주식 및 자산 관심 목록을 구성하고 모니터링하세요.
로그인 Premium Icon프리미엄 Help Menu
S&P 500
5,214.67
0.01%
US Tech 100
17,677.60
0.21%
다우존스 지수
39,469.12
0.21%
Bitcoin
60,728.36
-3.67%
Registration Strip Icon for monitor 브라질 증권 거래소, NASDAQ, NYSE, AMEX, LSE 등 주요 거래소에서의 다양한 실시간 주식 시세를 모니터링합니다.
등록
  1. 홈
  2. 인베스팅
  3. 주식
  4. 미국
  5. NASDAQ
  6. Madrigal Pharmaceuticals Inc (MDGL)

  7. Madrigal Pharmaceuticals Inc (MDGL) 뉴스

MDGL

Madrigal Pharmaceuticals (MDGL)

Madrigal Pharmaceuticals Inc
일자:
정렬 기준:
 검색 관련기사 보기:NASDAQ:MDGL
일자시간출처헤드라인심볼기업
2024/05/0805:36Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MDGLMadrigal Pharmaceuticals Inc
2024/05/0805:34Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:MDGLMadrigal Pharmaceuticals Inc
2024/05/0805:29Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:MDGLMadrigal Pharmaceuticals Inc
2024/05/0722:00Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:MDGLMadrigal Pharmaceuticals Inc
2024/05/0720:06Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MDGLMadrigal Pharmaceuticals Inc
2024/05/0720:00GlobeNewswire Inc.Madrigal Pharmaceuticals Reports First-Quarter 2024 Financial Results and Provides Corporate UpdatesNASDAQ:MDGLMadrigal Pharmaceuticals Inc
2024/04/2505:00GlobeNewswire Inc.Madrigal Statement on the Passing of Dr. Stephen HarrisonNASDAQ:MDGLMadrigal Pharmaceuticals Inc
2024/04/2321:00GlobeNewswire Inc.Madrigal Pharmaceuticals to Release First-Quarter 2024 Financial Results and Host Webcast on May 7, 2024NASDAQ:MDGLMadrigal Pharmaceuticals Inc
2024/04/1705:05GlobeNewswire Inc.Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)NASDAQ:MDGLMadrigal Pharmaceuticals Inc
2024/04/0921:00GlobeNewswire Inc.Madrigal Pharmaceuticals Announces U.S. Availability of Rezdiffra™ (resmetirom) for the Treatment of Patients with Noncirrhotic NASH with Moderate to Advanced Liver FibrosisNASDAQ:MDGLMadrigal Pharmaceuticals Inc
2024/04/0405:05GlobeNewswire Inc.Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)NASDAQ:MDGLMadrigal Pharmaceuticals Inc
2024/03/1912:58GlobeNewswire Inc.Madrigal Pharmaceuticals Announces Pricing of Upsized $600 Million Public OfferingNASDAQ:MDGLMadrigal Pharmaceuticals Inc
2024/03/1905:04GlobeNewswire Inc.Madrigal Pharmaceuticals Announces Proposed Public OfferingNASDAQ:MDGLMadrigal Pharmaceuticals Inc
2024/03/1520:30IH Market NewsAdobe Stock Drops Following Below-Estimate Projections, Cardlytics Surges with Unexpected Profit, and More NewsNASDAQ:MDGLMadrigal Pharmaceuticals Inc
2024/03/1505:15GlobeNewswire Inc.Madrigal Pharmaceuticals Announces FDA Approval of Rezdiffra™ (resmetirom) for the Treatment of Patients with Noncirrhotic Nonalcoholic Steatohepatitis (NASH) with Moderate to Advanced Liver FibrosisNASDAQ:MDGLMadrigal Pharmaceuticals Inc
2024/03/0706:05GlobeNewswire Inc.Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)NASDAQ:MDGLMadrigal Pharmaceuticals Inc
2024/03/0522:00GlobeNewswire Inc.Madrigal Pharmaceuticals Announces EMA Validation of its Marketing Authorization Application for Resmetirom for the Treatment of NASH/MASH with Liver FibrosisNASDAQ:MDGLMadrigal Pharmaceuticals Inc
2024/02/2821:10Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MDGLMadrigal Pharmaceuticals Inc
2024/02/2821:01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MDGLMadrigal Pharmaceuticals Inc
2024/02/2821:01GlobeNewswire Inc.Madrigal Pharmaceuticals Appoints Mardi C. Dier as Chief Financial OfficerNASDAQ:MDGLMadrigal Pharmaceuticals Inc
2024/02/2821:00GlobeNewswire Inc.Madrigal Pharmaceuticals Provides Corporate Updates and Reports Fourth Quarter and Full Year 2023 Financial ResultsNASDAQ:MDGLMadrigal Pharmaceuticals Inc
2024/02/2820:32Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:MDGLMadrigal Pharmaceuticals Inc
2024/02/2122:00GlobeNewswire Inc.Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)NASDAQ:MDGLMadrigal Pharmaceuticals Inc
2024/02/1504:50Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:MDGLMadrigal Pharmaceuticals Inc
2024/02/1423:21Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:MDGLMadrigal Pharmaceuticals Inc
2024/02/1407:55Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:MDGLMadrigal Pharmaceuticals Inc
2024/02/0822:00GlobeNewswire Inc.Madrigal Pharmaceuticals Announces Publication of the Phase 3 MAESTRO-NASH Trial of Resmetirom in the New England Journal of MedicineNASDAQ:MDGLMadrigal Pharmaceuticals Inc
2024/02/0706:05GlobeNewswire Inc.Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)NASDAQ:MDGLMadrigal Pharmaceuticals Inc
2024/01/3007:25Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:MDGLMadrigal Pharmaceuticals Inc
2024/01/2922:00GlobeNewswire Inc.Madrigal Pharmaceuticals Announces Additions to Its Leadership TeamNASDAQ:MDGLMadrigal Pharmaceuticals Inc
 검색 관련기사 보기:NASDAQ:MDGL

최근 히스토리

AMEX
XLE
Energy Select Sector SPDR
USOTC
ADDYY
Adidas (QX)
SPI
SP500
S&P 500
NYSE
DIS
Walt Disney
NYSE
VZ
Verizon Communications
USOTC
BNPQY
BNP Paribas (QX)
NYSE
MCD
McDonalds
CCOM
US30
US 30
FX
USDEUR
US Dollar vs Euro
USOTC
BASFY
BASF (QX)
CCOM
US500
US 500
USOTC
DTEGY
Deutsche Telekom (QX)
USOTC
RHHBY
Roche (QX)
AMEX
XLF
Financial Select Sector
NASDAQ
QQQ
Invesco QQQ Trust Series 1
Delayed Upgrade Clock
ADVFN Logo

대한변국
회사 소개
사업
Popular
앱 받기

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관

© 2024 ADVFN PLC - 모든 권리 보유